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“Nothing great was ever achieved without enthusiasm.”
Ralph Waldo Emerson
It is with great expectations and enthusiasm that we present to you the first issue of yournew Journal. The JTO has an international panel of “world class” associate editors who
have joined together in this new endeavor. Our associate editors have expertise in
radiology, pathology, translational research, thoracic surgery, radiation oncology, and
medical oncology. Our goal is to develop JTO into a premier oncology journal.
I would personally like to thank Dr. Heine Hansen for all of his hard work and
leadership of the IASLC. There is no other single individual who has had such a positive
influence on our organization over the past 20 years. For many of us, he is “Mr. Lung
Cancer.” He has been a strong influence on the careers of countless individuals in this
organization. Personally, he has provided me with abundant opportunities to be involved
in IASLC activities. Dr. Hansen was the first and only Editor of the official journal of the
IASLC until his retirement this past month. For all that you have done for us, Doctor
Hansen, we extend to you our heartfelt thanks and appreciation.
Why the new journal? This is a frequently asked question. The short answer is that JTO
provides the IASLC with new opportunities and expands our horizon. First of all, as the new
name implies, we have now extended the scope our journal covers to more than just lung
cancer. Many of our members are actively involved in the diagnosis and treatment of other
thoracic malignancies such as mesothelioma, esophageal cancer, thymomas, etc. Additionally,
many of us are involved in the care of patients with metastatic disease to the chest, e.g.,
malignant pleural effusion or resection of pulmonary metastasis. The JTO is a new outlet for
publishing scientific observations related to these other malignancies that affect the thorax.
Secondly, our new publisher, Lippincott, Williams and Wilkins, has brought us into the
modern electronic publishing age. All articles are now submitted electronically, and the total
review process is electronic. The electronic format is through Editorial Manager, an electronic
system that is used to manage over 100 other journals. Accordingly, the system is well-
designed and functions very well with minimal difficulties. New users will find it user friendly,
but if problems arise, there is a web link to the managing editor, Mary Sharkey. Just contact
her, and she will help solve the problem.
The new electronic manuscript managing system has allowed the editorial board to
set ambitious goals for review of your manuscripts. We have set five weeks as the time
for completion of first review. JTO reviewers are asked to submit their review on
manuscripts within two weeks. We know that you want an answer quickly, and we plan
to deliver. Our goal for time from first submission to publication is four months. For the
first 50 manuscripts submitted, the average number of days to first decision was 28. The
average number of days between the reviewer agreeing to review and submitting this
review was 12. Sixty percent of the reviewers completed their review within 14 days, as
requested. Hence, we are off to an excellent start. However, since this is just the
beginning, we plan to get better with more experience. Our goal is to provide you, the
reader, and our IASLC members with a superb new journal. In return, the editorial board
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and I would ask that you submit your excellent manuscripts
for consideration of publication. The JTO web site is www.
JTO.org, and there you will find the link to the manuscript
submission site.
As you will see by reviewing this issue, we have
included some new features. First, we have created a new
series titled “State of the Art: Concise Review.” In this issue,
Dr. Edward Hirschowitz and associates have reviewed the
current status of vaccines in lung cancer clinical trials. Drs.
Schild and Bogart have reviewed the innovations in thoracic
radiotherapy. We are also featuring a “Gene or Pathway of
the Month” to help educate all of us on lung cancer biology.
Finally, we have instituted an image of the month for your
enjoyment and education. We may even come up with an
occasional quiz for our readers in future issues.
Finally, I consider it an honor and privilege to be the first
editor of the new IASLC official journal. With the assistance of
the associate editors, we will do everything that we can to make
THE JOURNAL OF THORACIC ONCOLOGY a top ranked
journal within the next five years.
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